Home
Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

Trick or Trade December 16, 2025

Milestone in the NEWS
MONTREAL and CHARLOTTE, Milestone® (MIST) announced that the U.S. FDA approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Trick or Trade
December 16, 2025

Other Articles